Related Experiment Video

Updated: Sep 27, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Induction of apoptosis in cancer: new therapeutic opportunities

Han-Fei Ding1, David E Fisher

  • 1Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo, OH, USA.

Annals of Medicine
|January 14, 2003
PubMed

Insights

Cancer cells proliferate uncontrollably due to oncogenes, but this triggers apoptosis, particularly via the ARF-p53 pathway. Suppressing apoptosis is key to tumor development, offering therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Autonomous cell proliferation, a cancer hallmark, is driven by oncogenes.
  • Oncogene activation paradoxically triggers apoptosis through various pathways.
  • The ARF-p53 pathway is critical in mediating oncogene-induced apoptosis.

Purpose of the Study:

  • To elucidate the role of the ARF-p53 pathway in oncogene-induced apoptosis.
  • To understand how apoptosis suppression contributes to tumor development.
  • To explore therapeutic strategies targeting apoptotic pathways in cancer.

Main Methods:

  • Analysis of oncogene-induced apoptosis pathways.
  • Investigation of tumor suppressor gene inactivation in cancer.
  • Examination of apoptotic defects in cancer cells.

Main Results:

  • The ARF-p53 pathway plays a significant role in oncogene-induced apoptosis.
  • Inactivation of p53 and other tumor suppressors is crucial for tumor progression by suppressing apoptosis.
  • Cancer cells exhibit defects in apoptotic pathways but remain sensitive to apoptosis due to deregulated proliferation.

Conclusions:

  • Understanding oncogene and tumor suppressor roles is vital for cancer genetics and therapy.
  • Defects in apoptotic pathways in cancer cells present opportunities for clinical intervention.
  • Targeting apoptosis offers promising avenues for cancer treatment development.

More Related Videos

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal11:21

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal

Published on: January 26, 2019

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.